title: A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.
abstract: A-61827 (A-60969 is the hydrochloric salt of A-61827) is a new aryl-fluoronaphthyridine which is active against aerobic and anaerobic bacteria. The MICs of A-61827 for 90% of strains (MIC90) of staphylococci and streptococci were less than or equal to 1 microgram/ml and were generally 1 to 4 twofold dilutions less than those of ciprofloxacin for these bacteria. The MIC90S of A-61827 for members of the family Enterobacteriaceae and Pseudomonas aeruginosa were also less than or equal to 1 microgram/ml. Ciprofloxacin was 1 to 3 twofold dilutions more active than A-61827 against these gram-negative bacteria. Neisseria gonorrhoeae, Campylobacter jejuni, and Haemophilus influenzae were susceptible to less than 0.06 microgram of A-61827 per ml. The MIC90 of A-61827 for Legionella pneumophila was 0.25 microgram/ml. A-61827 was as potent or 1 to 2 twofold dilutions more potent than ciprofloxacin against these organisms. The MIC90 of A-61827 for all anaerobic bacteria was less than or equal to 4 micrograms/ml compared with less than or equal to 32 micrograms/ml for ciprofloxacin. In mouse protection tests, A-61827 was as active as ciprofloxacin against Escherichia coli, P. aeruginosa, and Salmonella typhimurium and 5 to 10 times more active than ciprofloxacin against Staphylococcus aureus and Streptococcus pyogenes. A-61827 was as active as ciprofloxacin against P. aeruginosa in a mouse pyelonephritis model and more active than ciprofloxacin and metronidazole in a mouse Bacteroides fragilis abscess model. After oral administration of 100 mg/kg to mice, the peak concentrations of A-61827 and ciprofloxacin in serum were 2.3 and 2.4 micrograms/ml and the half-lives in serum were 3.9 and 1.2 h, respectively.
authors.affiliation: Anti-Infective Research Division, Abbott Laboratories, Abbott Park, Illinois 60064.
authors.forename: P B
authors.initials: PB
authors.lastname: Fernandes
authors.forename: D T
authors.initials: DT
authors.lastname: Chu
authors.forename: R N
authors.initials: RN
authors.lastname: Swanson
authors.forename: N R
authors.initials: NR
authors.lastname: Ramer
authors.forename: C W
authors.initials: CW
authors.lastname: Hanson
authors.forename: R R
authors.initials: RR
authors.lastname: Bower
authors.forename: J M
authors.initials: JM
authors.lastname: Stamm
authors.forename: D J
authors.initials: DJ
authors.lastname: Hardy
mesh_terms: D000038:Abscess / Q000188:drug therapy; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001420:Bacteria, Aerobic / Q000187:drug effects*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001442:Bacteroides Infections / Q000188:drug therapy; D002118:Calcium / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D002939:Ciprofloxacin / Q000493:pharmacokinetics / Q000494:pharmacology; D004195:Disease Models, Animal; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D006863:Hydrogen-Ion Concentration; D008274:Magnesium / Q000494:pharmacology; D051379:Mice; D009287:Naphthyridines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D002939:Ciprofloxacin; C055185:tosufloxacin; D008274:Magnesium; D002118:Calcium